Key Findings
For treating the high numbers of mental & neural disorders, neurostimulation will be playing a crucial role where medication drugs will not yield as much as it requires. The Europe market is proliferating at a CAGR of 9.35% through the forecasting years of 2019-2027.

Market Insights
The supply chain’s major focus is on driving down the costs of neurostimulation devices to increase market revenue in Europe. In 2018, revenue of neurostimulation device market in Germany was valued at $XX million. By 2027, the market is expected to reach $XX million, at a CAGR of xx% during forecasted period 2019-2027. According to the Federal Statistical Office (Destatis), Health expenditure in Germany exceeded the threshold of 1 billion euros per day for the first time in 2017. Compared with 2016, the Federal Statistical Office (Destatis) forecasts xx% increase in health expenditure to XX billion euros in 2017.

Competitive Insights
Some of the other major market players are Cogentix Medical Inc., St. Jude Medical Inc. (acquired by Abbott Laboratories), Aleva Neurotherapeutics SA, Boston Scientific Corporation, Helius Medical Technologies, The Magstim Company Limited, Cyberonics Inc., Neuronetics Inc., Depuy Synthes Companies, Ekso Bionics Holding Inc., Medtronic PLC, Dr. Langer Medical GmBH, Ectron Limited, Nevro Corp. and Hocoma AG.